The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...

This time, Tecvayli excelled as a solo agent, reducing the risk of disease progression or death by 71% over standard of care ...

Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...

Among patients with relapsed or refractory multiple myeloma, Tecvayli (teclistamab-cqyv) monotherapy was associated with a 71 ...

Johnson & Johnson reports Phase 3 results showing Tecvayli reduced disease progression and deaths in multiple myeloma ...

Johnson & Johnson announces positive results from phase 3 MajesTEC-9 study of Tecvayli in patients with multiple myeloma: Raritan, New Jersey Friday, January 16, 2026, 10:00 Hrs [ ...

How Does Darzalex Faspro Work for Multiple Myeloma? Darzalex Faspro is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by ...

Napa Therapeutics Ltd. has identified ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of inflammatory disorders, metabolic diseases, cancer, ...